Cellular Dynamics and Roche Collaboration
CDI initiated a 2 year standard supply collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY).
iCell Cardiomyocytes, induced pluripotent stem cell (iPSC) derived human heart cells, will be incorporated into Roche’s drug development.
CDI and Roche initiated their collaboration in 3/09 to test the ability of the cardiomyocytes to predict drug-induced, potentially life-threatening, cardiac arrhythmias. These studies included longitudinal genetic and molecular characterizations of the cardiomyocytes and assessment of their performance across a variety of established and novel testing platforms designed to detect possible cardiotoxic effects of developing compounds early in their development cycle.
The Bottom Line: This transition to a standard supply agreement is an important milestone for CDI and Roche to develop demonstrated an efficient tool to reveal potential cardiotoxicity in their drug development candidates. CDI developed iCell Cardiomyocytes as a cardiac cell model that reflects human biology with a manufacturing process to deliver the cells in the quantity, quality and purity that customers require to accomplish their drug discovery and toxicity testing research.
